Cellectis Market Cap ($85.44 Million)
Market Cap & Net Worth: Cellectis (ALCLS)
Cellectis market cap. Cellectis (PA:ALCLS) has a market capitalization of $85.44 Million (€73.08 Million) as of November 7, 2026. Listed on the PA stock exchange, this France-based company holds position #19558 globally and #294 in its home market, demonstrating a -8.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellectis's stock price €1.01 by its total outstanding shares 72718974 (72.72 Million). Also see ALCLS cash flow metrics for how efficiently the company converts equity into cash flow.
Cellectis Market Cap History (2015–2026)
Cellectis market cap history from 2015 to 2026. Data shows change from $2.37 Billion to $85.44 Million (-24.88% CAGR). Check current stock price of Cellectis for real-time trading data and today's change.
Index Memberships
Cellectis is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$38.14 Billion | 0.22% | #20 of 34 |
Weight: Cellectis's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellectis Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellectis's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALCLS year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.70x
Cellectis's market cap is 4.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $42.58 Million | -$63.92 Million | 32.36x | N/A |
| 2017 | $2.03 Billion | $25.19 Million | -$99.37 Million | 80.47x | N/A |
| 2018 | $1.28 Billion | $12.73 Million | -$78.69 Million | 100.70x | N/A |
| 2019 | $1.33 Billion | $15.19 Million | -$90.69 Million | 87.76x | N/A |
| 2020 | $2.07 Billion | $73.95 Million | -$72.57 Million | 28.05x | N/A |
| 2021 | $632.52 Million | $73.95 Million | -$86.28 Million | 8.55x | N/A |
| 2022 | $168.93 Million | $19.17 Million | -$98.69 Million | 8.81x | N/A |
| 2023 | $234.98 Million | $755.00K | -$101.06 Million | 311.24x | N/A |
| 2024 | $138.58 Million | $41.51 Million | -$36.76 Million | 3.34x | N/A |
| 2025 | $356.64 Million | $75.92 Million | -$70.35 Million | 4.70x | N/A |
Competitor Companies of ALCLS by Market Capitalization
Companies near Cellectis in the global market cap rankings as of November 7, 2026. Also see total assets of Cellectis for a full breakdown of the balance sheet.
Key companies related to Cellectis by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Cellectis (2015–2026)
Market capitalization of Cellectis from 2015 to today. Between 2015 and today, Cellectis's market cap moved from $2.37 Billion to $ 85.44 Million, with a yearly change of -24.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €85.44 Million | -76.04% |
| 2025 | €356.64 Million | +157.36% |
| 2024 | €138.58 Million | -41.03% |
| 2023 | €234.98 Million | +39.10% |
| 2022 | €168.93 Million | -73.29% |
| 2021 | €632.52 Million | -69.51% |
| 2020 | €2.07 Billion | +55.61% |
| 2019 | €1.33 Billion | +3.98% |
| 2018 | €1.28 Billion | -36.74% |
| 2017 | €2.03 Billion | +47.07% |
| 2016 | €1.38 Billion | -41.94% |
| 2015 | €2.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Cellectis was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.44 Million USD |
| MoneyControl | $85.44 Million USD |
| MarketWatch | $85.44 Million USD |
| marketcap.company | $85.44 Million USD |
| Reuters | $85.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more